Outlook: Making network pharmacology work
e-Therapeutics is a pioneer in network pharmacology, a novel approach to drug discovery that may result in faster and less risky development. The two lead programmes, ETS2101 (dexanabinol) in various cancers and ETS6103 (tramadol) in major depressive disorder, are progressing through early-stage clinical trials. Positive results would provide major value inflection points and facilitate out-licensing deals. The company is well funded, through to 2019, following the £38.9m (net) raise in March 2013.E-Therapeutics is a drug discovery company with a proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and utilizing public and proprietary chemical biology and multi-omics data. The therapeutic focus of Co.'s discovery activity is in areas of disease with unmet medical need, including immuno-oncology.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.